Downregulation of sperm-associated antigen 5 inhibits melanoma progression by regulating forkhead box protein M1/A disintegrin and metalloproteinase 17/NOTCH1 signaling

References

• Lugovic-Mihic L, Cesic, D, Vukovic, P, et al. Melanoma Development: current Knowledge on Melanoma Pathogenesis. Acta Dermatovenerol Croat. 2019;27(3):163–168.
   PubMed Web of Science ®Google Scholar
• Kozovska Z, Gabrisova V, Kucerova L. Malignant melanoma: diagnosis, treatment and cancer stem cells. Neoplasma. 2016;63(4):510–517.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang K, Wu Y, et al. Pinocembrin induces ER stress mediated apoptosis and suppresses autophagy in melanoma cells. Cancer Lett. 2018;431:31–42.
   PubMed Web of Science ®Google Scholar
• Sun Y, Hou Z, Luo B, et al. Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429. Bioengineered. 2021;12(1):4159–4173.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–142.
   PubMed Web of Science ®Google Scholar
• Pearlman RL, Montes de Oca MK, Pal HC, et al. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 2017;391:125–140.
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TMA, Agarwal D, Liu D-X, et al. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 2016;17(7):1004–1018.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Yagi M, Suzuki K. Duplicated insertion mutation in the microtubule-associated protein Spag5 (astrin/MAP126) and defective proliferation of immature Sertoli cells in rat hypogonadic (hgn/hgn) testes. Reproduction. 2006;132(1):79–93.
   PubMed Web of Science ®Google Scholar
• Gruber J, Harborth J, Schnabel J, et al. The mitotic-spindle-associated protein astrin is essential for progression through mitosis. J Cell Sci. 2002;115(Pt 21):4053–4059.
   PubMed Web of Science ®Google Scholar
• Li M, Li A, Zhou S, et al. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cance. J Hematol Oncol. 2019;12(1):14.
   PubMedGoogle Scholar
• Yuan LJ, Li J-D, Zhang L, et al. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis. 2014;5:e1247.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li S, Yang X, et al. miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res. 2016;35:60.
   PubMed Web of Science ®Google Scholar
• Liu G, Liu S, Cao G, et al. SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the wnt/beta-catenin pathway. Exp Cell Res. 2019;379(1):83–91.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang Y, He J. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5. J Clin Lab Anal. 2021;35(7):e23853.
   PubMed Web of Science ®Google Scholar
• Kruiswijk F, Hasenfuss SC, Sivapatham R, et al. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene. 2016;35(17):2166–2177.
   PubMed Web of Science ®Google Scholar
• Miyashita A, Fukushima S, Nakahara S, et al. Investigation of FOXM1 as a potential new target for melanoma. PLoS One. 2015;10(12):e0144241.
   PubMed Web of Science ®Google Scholar
• Koo CY, Muir KW, Lam EW. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819(1):28–37.
   PubMed Web of Science ®Google Scholar
• Li Z, Li H, Chen J, et al. SPAG5 promotes osteosarcoma metastasis via activation of FOXM1/MMP2 axis. Int J Biochem Cell Biol. 2020;126:105797.
   PubMed Web of Science ®Google Scholar
• Zhang C, Han X, Xu X, et al. FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. Cell Death Dis. 2018;9(5):469.
   PubMedGoogle Scholar
• Jiao X, Yu W, Qian J, et al. ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1. BMC Cancer. 2018;18(1):570.
   PubMedGoogle Scholar
• Li DD, Zhao C-H, Ding H-W, et al. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. Cell Prolif. 2018;51(5):e12480.
   PubMed Web of Science ®Google Scholar
• Li W, Wang, D, Sun, X, et al. ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways. Int J Mol Med. 2019;43(2):914–926.
   PubMed Web of Science ®Google Scholar
• Saha SK, Choi HY, Yang G-M, et al. GPR50 promotes hepatocellular carcinoma progression via the notch signaling pathway through direct interaction with ADAM17. Mol Ther Oncolytics. 2020;17:332–349.
   PubMed Web of Science ®Google Scholar
• Cireap N, Narita D. Molecular profiling of ADAM12 and ADAM17 genes in human malignant melanoma. Pathol Oncol Res. 2013;19(4):755–762.
   PubMed Web of Science ®Google Scholar
• Huang L, Chen J, Quan J, et al. Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3beta axis. Bioengineered. 2021;12(1):3065–3076.
   PubMed Web of Science ®Google Scholar
• He X, Wang J, Wei W, et al. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. Cancer Biol Ther. 2016;17(2):188–198.
   PubMed Web of Science ®Google Scholar
• Barrett CS, Millena AC, Khan SA. TGF-beta effects on prostate cancer cell migration and invasion require FosB. Prostate. 2017;77(1):72–81.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kang W, Lu X, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway. Cell Cycle. 2018;17(15):1886–1900.
   PubMed Web of Science ®Google Scholar
• Ye Y, Huang S, Wu Y. UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway. Cancer Manag Res. 2019;11:2339–2348.
   PubMed Web of Science ®Google Scholar
• Yao Y, Chen X, Yang H, et al. Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J Exp Clin Cancer Res. 2019;38(1):318.
   PubMedGoogle Scholar
• Zhang Y, Dai J, Deng H, et al. miR-1228 promotes the proliferation and metastasis of hepatoma cells through a p53 forward feedback loop. Br J Cancer. 2015;112(2):365–374.
   PubMed Web of Science ®Google Scholar
• Xu S, Xiao Y, Zeng S, et al. Piperlongumine inhibits the proliferation, migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflamm Res. 2018;67(3):233–243.
   PubMed Web of Science ®Google Scholar
• Hwang HJ, Oh M-S, Lee DW, et al. Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells. J Exp Clin Cancer Res. 2019;38(1):258.
   PubMedGoogle Scholar
• Han H, Jain AD, Truica MI, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36(5):483–497 e15.
   PubMed Web of Science ®Google Scholar
• Huang GX, Wang Y, Su J, et al. Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma. Cancer Lett. 2017;410:1–11.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang C, Ma X, et al. High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFbeta1. J Pathol. 2019;247(4):481–493.
   PubMed Web of Science ®Google Scholar
• He J, Green AR, Li Y, et al. SPAG5: an emerging oncogene. Trends Cancer. 2020;6(7):543–547.
   PubMed Web of Science ®Google Scholar
• Zhu C, Menyhart O, Győrffy B, et al. The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy. BMC Cancer. 2019;19(1):1046.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang J, He X, et al. High expression of SPAG5 sustains the malignant growth and invasion of breast cancer cells through the activation of Wnt/β-catenin signalling. Clin Exp Pharmacol Physiol. 2019;46(6):597–606.
   PubMed Web of Science ®Google Scholar
• Yang T, Tian S, Wang L, et al. MicroRNA-367-3p overexpression represses the proliferation and invasion of cervical cancer cells through downregulation of SPAG5-mediated Wnt/beta-catenin signalling. Clin Exp Pharmacol Physiol. 2020;47(4):687–695.
   PubMed Web of Science ®Google Scholar
• Zhang M, Sha, L, Hou, N, et al. High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer. Biosci Rep. 2020;40(2):BSR20193087.
   PubMedGoogle Scholar
• Liu H, Hu J, Wei R, et al. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying beta-catenin degradation. J Exp Clin Cancer Res. 2018;37(1):229.
   PubMedGoogle Scholar
• Yang YF, Zhang M-F, Tian Q-H, et al. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17(1):117.
   PubMed Web of Science ®Google Scholar
• Wang L, Cao L, Wen C, et al. LncRNA LINC00857 regulates lung adenocarcinoma progression, apoptosis and glycolysis by targeting miR-1179/SPAG5 axis. Hum Cell. 2020;33(1):195–204.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Y, Zeng H, et al. Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer. J Nanobiotechnology. 2021;19(1):189.
   PubMed Web of Science ®Google Scholar
• Fang W, Qian J, Wu Q, et al. ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma. J Surg Res. 2017;220:223–233.
   PubMed Web of Science ®Google Scholar
• Baumgart A, Seidl S, Vlachou P, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010;70(13):5368–5378.
   PubMed Web of Science ®Google Scholar
• Bozkulak EC, Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol. 2009;29(21):5679–5695.
   PubMed Web of Science ®Google Scholar
• Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A. 2005;102(26):9182–9187.
   PubMed Web of Science ®Google Scholar
• Ma Z, Gao Y, Liu W, et al. CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate Cancer. Dis Markers. 2020;2020:8899924.
   PubMed Web of Science ®Google Scholar